Medtechs Drive To Keep The Status Quo In A Year Like No Other

06 Dec 2021

The performances of the leading medtechs in the first year of the COVID-19 pandemic were impossible to compare and certainly unrepresentative of normal business cycles and competitive activity. Elective care was largely put on hold and emergency needs boosted exceptional demand for certain product types. More than anything else, 2020 tested management skills and planning.

Demand for certain types of medtech, industrial operations, supply chains and distribution systems were all impacted to some extent by COVID-19 in 2020. So were product development milestones, clinical trials, regulatory clearances and approval timings.

During the pandemic, leading orthopedic and some cardiology suppliers saw sharply negative outcomes, while the opposite was the case for...